Organizations aim to advance precision oncology and biomarker-driven research.
Caris Life Sciences, an artificial intelligence (AI) TechBio company, announced that Sarah Cannon Research Institute (SCRI), an oncology research organization, has officially joined the Caris Precision Oncology Alliance (POA). According to Caris, the POA is a network of cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
"SCRI and Caris share a commitment to advancing therapies and expanding access to molecular diagnostic approaches for patients in the community," said Andrew McKenzie, PhD, VP, personalized medicine, SCRI; scientific director, Genospace. "We are pleased to join the Caris Precision Oncology Alliance and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer."
Reference: The Caris Precision Oncology Alliance Welcomes Sarah Cannon Research Institute. PR Newswire. October 26, 2023. Accessed October 27, 2023. https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-sarah-cannon-research-institute-301968199.html
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.